Results 121 to 130 of about 27,357 (215)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants

Journal of Health Economics and Outcomes Research, 2015
# Objectives Compare the cost of the primary prophylaxis of invasive fungal infections (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National ...
Santiago Grau, Carlos Solano, Carol García-Vidal, Isidro Jarque, Jon A. Barrueta, Carmen Peral, Irene Rodríguez, Darío Rubio-Rodríguez, Carlos Rubio-Terrés   +8 more
doaj   +1 more source

Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2

Journal of the Endocrine Society, 2019
We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively.
G. Thompson, Katharina R. Beck, M. Patt, D. Kratschmar, A. Odermatt   +4 more
semanticscholar   +1 more source

Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology, 2012
INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.
Amir A Tahami Monfared, Amy K O’Sullivan, Coleman Rotstein, George Papadopoulos   +3 more
doaj   +1 more source

Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Journal of Antimicrobial Chemotherapy, 2019
OBJECTIVES Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment.
J. Periselneris, L. Nwankwo, S. Schelenz, A. Shah, D. Armstrong-James   +4 more
semanticscholar   +1 more source

In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species

Antimicrobial Agents and Chemotherapy, 2019
Mucormycosis is an emerging disease with high mortality rates. Few antifungal drugs are active against Mucorales. ABSTRACT Mucormycosis is an emerging disease with high mortality rates. Few antifungal drugs are active against Mucorales.
Florencia Leonardelli, Daiana Macedo, Catiana Dudiuk, Laura Theill, Matías S. Cabeza, S. Gamarra, G. García-Effrón   +6 more
semanticscholar   +1 more source

Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders—A Single-Centre Study

Journal of Fungi
Introduction: Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability in bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). Materials and
Karolina Liszka, Paweł Marschollek, Dawid Przystupski, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Igor Olejnik, Zuzanna Gamrot, Natalia Haze, Agnieszka Kwella, Paulina Zalewska, Matylda Resztak, Marek Ussowicz, Krzysztof Kałwak   +12 more
doaj   +1 more source

Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review

Frontiers in Pharmacology
BackgroundPosaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals.
Ruochen Qu, Ruochen Qu, Yan Liu, Yan Liu, Yan Zhao, Yan Zhao, Ziyi Wang, Ziyi Wang, Shizhao Yuan, Shuai Liu, Jing Yu, Jing Yu   +11 more
doaj   +1 more source

Estudi d'utilització d'antifúngics sistèmics a l'Hospital Universitari Vall d'Hebron [PDF]

, 2011
Objectius: Descriure les principals característiques de la utilització dels antifúngics sistèmics a l'Hospital Universitari Vall d'Hebron (HUVH) i avaluar la seva adequació.
López Guerrero, Eva, Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona. Facultat de Medicina, Vidal Guitart, Xavier   +3 more
core   +1 more source

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

Drug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj  

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections

Clinical Pharmacology: Advances and Applications, 2015
Nathan P Wiederhold Departments of Pathology and Medicine/Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Reference Laboratories, San Antonio, TX, USA Abstract: Posaconazole is a broad-spectrum triazole ...
Wiederhold NP
doaj